Biospecimen bone infection registry finds higher MRSA rate in North America
Click Here to Manage Email Alerts
An international, biospecimen registry on Staphylococcus aureus in fixation or arthroplasty showed higher rates of MRSA in North American patients and poorer subjective outcomes among those with MRSA vs. methicillin-sensitive S. aureus.
Researchers from the AO trauma Clinical Priority Program (CPP) collected microbiological and immunological data, including bacterial isolates, blood and sera, from 292 patients with long bone and joint infections.
“Methicillin-resistant S. aureus (MRSA) was detected in 82 patients (28.4%), with the highest proportion found among patients from North American sites (n=39, 48.8%) and the lowest from Central European sites (n=18, 12.2%),” the researchers wrote in the study. “Although patients improved with treatment, less than two-thirds were cured in 1 year. At 12-month follow-up, patient-reported outcome scores were worse for patients with MRSA infections,” they wrote.
The researchers also stressed the “serious nature” of S. aureus infection of long bones and joints, adding that 4.8% of the cohort died within the first study year and that 60% had been treated for the same infection in the previous 3 years.
“The AO Trauma CPP Bone Infection Registry is an annotated biospecimen repository that can be utilized to elucidate relationships between patient demographics, comorbidities, treatment modality, patent-specific host immunity to the causal pathogen(s) and outcomes, in prospective studies,” the researchers concluded.
Collapse
Read more about
Click Here to Manage Email Alerts